Essential hypertension causes high rates of morbidity and mortality, primarily due to its complications, and its development is regulated by genetic risk and environmental factors. However, until recent genomewide association studies (GWASs) were reported, the genetic factors were unknown. Two GWASs on systolic blood pressure (SBP), diastolic blood pressure (DBP) and hypertension in Caucasians-Global Blood Pressure Genetics (Global BPgen) and Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE)-reported 51 single-nucleotide polymorphisms (SNPs) in 12 loci at Po4Â10 À7 . Because the prevalence, age of onset and severity of complications of hypertension vary between ethnic groups, we wanted to investigate these results in other ethnic groups. We examined the association of 27 of the 51 SNPs in 8512 unrelated individuals from Korean Association REsource (KARE), a GWAS that was based on epidemiological cohorts in Korea. Four loci-ATP2B1 (ATPase, Ca ++ transporting, plasma membrane 1), CSK (c-src tyrosine kinase), CYP17A1 (cytochrome P450 17A1) and PLEKHA7 (pleckstrin homology domain-containing family A member 7)-were associated with blood pressure and hypertension in the Korean population.
INTRODUCTION
Hypertension, which is defined as systolic blood pressure (SBP) of X140 mm Hg and/or diastolic blood pressure (DBP) of X90 mm Hg, is a polygenic disease 1 that is regulated by complex interactions between networked genes and environmental stimuli. Hypertension likely contributes to the development of metabolic syndrome and cardiovascular risk factors. 2, 3 To identify the genetic risk factors for hypertension, two genomewide association studies (GWASs) were recently reported by the Global Blood Pressure Genetics (Global BPgen) 4 consortium and the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) consortium. 5 The study by Global BPgen performed three-stage analyses of 118 547 subjects of primarily European ancestry, 4 identifying the significant genomewide (Po5Â10 -7 ) associations in eight loci that are listed in Supplementary Table S1a. In another GWAS, the CHARGE consortium, 5 examining 29 136 individuals from six population-based cohorts, conducted a meta-analysis of all significant single-nucleotide polymorphisms (SNPs; Po1Â10 -6 ). Supplementary Table S1b lists the 43 SNPs that were significantly associated with SBP, DBP or hypertension status.
In a previous study, we reported the GWAS results of Korean Association REsource (KARE) using 8842 unrelated individuals who were recruited from two community-based epidemiological cohorts. 6 Eight novel loci associated with seven quantitative traits and a plasma membrane calcium pump, ATP2B1(ATPase, Ca ++ transporting, plasma membrane 1), were significantly associated with blood pressure in Koreans. In this study, we analyzed the association of the SNPs that were reported by two blood pressure consortiums, Global BPgen and CHARGE, to determine whether these SNPs also influenced blood pressure and hypertension risk in the Korean population.
MATERIALS AND METHODS Subjects
Subjects and their genotypes were reported in a previous GWAS. 6 In brief, subjects came from two community-based cohorts, the rural community Ansung and the urban community Ansan, in Kyunggi-Do province, near Seoul, Korea. The initial numbers of individuals, aged 40-69 years, were 5018 and 5020 from Ansung and Ansan, respectively. This study was approved by the international review board committees of the Korea National Institute of Health.
The basic characteristics and blood pressures of the patients are listed in Table 1 . For this study, blood pressure measurements were taken three times in the supine position. Before the first measurement, participants rested for 5 min, and three measurements were taken at least 30 s apart. The average of the three measurements was used for this study. Hypertensive status was defined as having SBP of X140 mm Hg and/or DBP of X90 mm Hg, and normal controls were defined as having SBP of o120 mm Hg and DBP of o80 mm Hg, excluding the prehypertensive status.
Genotyping and quality control
Most DNA samples were isolated from the peripheral blood of participants and genotyped using Affymetrix Genomewide Human SNP array 5.0 (Affymetrix, Inc., Santa Clara, CA, USA). The quality controls are described in a previous report. 6 In brief, the accuracy of the genotyping was determined by Bayesian Robust Linear Modeling using the Mahalanobis distance genotyping algorithm. 7 Samples that had accuracies of o98% and a high missing genotype call rate (X4%), high heterozygosity (430%) or inconsistency in sex were excluded from subsequent analyses. Individuals who had any tumor were excluded. Related individuals whose estimated identity-by-state value was high (40.80) 8 were also excluded.
After the quality control steps, 8842 samples were selected. To analyze blood pressure traits, 330 subjects who had been treated with drugs that likely influenced blood pressure were also excluded. Finally, we used 8512 individuals. The 351 677 genotyped SNPs had a missing gene call rate o0.1, a minor allele frequency 40.01 and no deviation from the Hardy-Weinberg equilibrium (P41Â10 À6 ).
Genotype imputation
Of the 51 SNPs that were reported by Global BPgen and CHARGE, only 10 occurred in the KARE genotype data. To maximize the association analysis in Koreans, we used imputation methods using the Chinese-Japanese HapMap data set. An additional 17 imputed SNPs (see Table 2 , column G/I) were analyzed in this study.
The detailed imputation procedure has been published earlier. 9 In brief, the KARE data set, comprising 351 677 SNPs for 8842 individuals, was merged with that of International HapMap Phase II JPT (Japanese)+HCB (Chinese) panel 2, resulting in 2 180 896 SNPs. The genotypes of the KARE individuals were imputed using PLINK (version 1.07, http://pngu.mgh.harvard.edu/~purcell/ plink/). 10 A total of 333 418 SNPs were shared between the KARE and HapMap data sets. The concordance rates for these SNPs were calculated, for which the first quartile and median were 0.964 and 0.987, respectively. Profiling the concordance rates at various intervals of the key parameters that were reported by PLINK allowed us to develop a filtering scheme-PHWE 410 À6 , IMPUTED X0.9 and INFO X0.9-which improved the first quartile and median to 0.985 and 0.994, respectively.AQ3 From 1 026 596 SNPs that passed the filters, we selected an additional 17 SNPs that matched the 51 SNPs that were reported by the Global BPgen and CHARGE studies.
To identify differences between the KARE (Korean) and other populations (CHARGE, Global BPgen, CEU (European), HCB (Chinese), JPT (Japanese) and YRI (African)), pairwise F st distances (measures of genetic differentiation 11 ) were calculated for each tested SNP in Table 2 . F st measures the proportion of genetic diversity due to differences in allele frequencies between populations relative to the within-population variation. F st values were estimated using Arlequin ver. 3.1 (http://cmpg.unibe.ch/software/arlequin3/). 12 
Association tests
Quantitative trait analysis. Of the 8512 subjects in this study, 961 subjects were undergoing antihypertensive therapy. For quantitative analysis of SBP and DBP, these individuals were excluded, yielding a final sample size of 7551 individuals. Linear regression was used to analyze SBP and DBP as quantitative traits, controlling for the subject's cohort, age, sex and body mass index. Statistical analyses were performed using PLINK. 10 All tests were based on an additive model, and P-values were not adjusted for multiple tests.
Case-control analysis. In addition to 1007 subjects who had SBP of X140 mm Hg and/or DBP of X90 mm Hg, 961 subjects who were using antihypertensive medications were included, generating a total of 1968 cases. The 2029 prehypertensive subjects, defined as having 120 pSBP o140 mm Hg and/or 80 pDBP o90 mm Hg, were excluded from the control groups in the hypertension case-control analysis. The normotensive controls were defined as having SBP of o120 mm Hg and DBP of o80 mm Hg and without antihypertensive treatment. In the end, 1968 hypertensive cases and 4451 normotensive controls were used for the case-control study.
Logistic regression analysis was used for the hypertensive cases and normotensive controls, controlling for cohort, age, sex and body mass index as covariates. Statistical analyses were performed using PLINK. 10 All tests were based on an additive model, and P-values were not adjusted for multiple tests. The estimated sample sizes for 80% study power at a¼0.05 in Tables 2 and 3 were respectively based on CHARGE and KARE parameters, including minor allele frequency, effect size and mean value of blood pressure.
RESULTS
We analyzed 8512 individuals in the KARE study for their genotypic association with blood pressure and hypertension. The basic characteristics of the subjects are listed in Table 1 . Of the 51 significant SNPs, 10 that were reported by the Global BPgen and CHARGE were genotyped in the KARE study. To examine more SNPs, imputation was performed, and an additional 17 SNPs were analyzed.
The minor allele frequencies of the 27 SNPs in the KARE data were compared with those from the Global BPgen, CHARGE and dbSNP data. As shown in Table 2 , the allele frequencies in the KARE data were similar to those in the HCB (Han Chinese in Beijing, average F st 0.005) and JPT (Japanese in Tokyo, average F st 0.006) groups but differed from those of the Global BPgen, CHARGE and CEU cohorts (Caucasians in Europe, average F st 0.085, 0.057 and 0.075, respectively).
The association results are shown in Table 3 for SBP, DBP and hypertension, as are significant P-values. In all, 14 SNPs in 4 genes were significantly associated with blood pressure and hypertension with P-value o0.05.
The strongest signals were detected in the ATP2B1 gene region of chromosome 12q21.3 (P-value o5Â10 À7 for all three blood pressure traits). rs17249754 had the strongest association of the SNPs in the ATP2B1 gene region, and individuals with minor allele (A) of rs17249754 experienced significantly lower SBP (b¼À1.34 ± 0.26, P¼3.35Â10 À7 ), DBP (b¼À0.90±0.18, P¼3.76Â10 À7 ) and hypertension risk (odds ratio¼0.79, confidence interval 0.72-0.86, P¼1.60Â10 À7 ).
The second set of robust signals for all three blood pressure traits were detected in the CSK (c-src tyrosine kinase) gene region of chromosome 15q23-q25. In KARE, individuals who had minor allele (A) of rs1378942 showed significantly reduced SBP (b¼À1.42±0.34, P¼2.53Â10 À5 ), DBP (b¼À0.94±0.23, P¼4.20Â10 À5 ) and hypertension risk (odds ratio¼0.73, confidence interval 0.65-0.89, P¼2.09Â10 À7 ).
The remaining two signals were found in the CYP17A1 (cytochrome P450 17A1) and PLEKHA7 (pleckstrin homology domain-containing, family A member 7) loci. Individuals who had the minor allele (C) of rs11191548 in CYP17A1 experienced significantly reduced SBP (b¼À0.83±0.29, P¼4.76Â10 À3 ), DBP (b¼À0.51±0.20, P¼1.01Â10 À2 ) and hypertension risk (odds ratio¼0.84, confidence interval 0.76-0.92, P¼4.85Â10 À4 ). With regard to PLEKHA7, individuals who had the minor allele (T) of rs381815 showed significantly increased SBP (b¼0.77±0.34, P¼2.28Â10 À2 ), DBP (b¼0.35±0.23, P40.05) and hypertension risk (odds ratio¼1.19, confidence interval 1.07-0.33, P¼1.70Â10 À3 ).
To determine the differences in genetic effects between populations, the effects of the SNPs, expressed as the b-values of the regression analysis for SBP, were compared with those in Caucasians, as shown in Figure 1 . All four SNPs had similar effects as those that have been reported, and except for rs1378942 in CSK, the SNPs had similar effect sizes as those in Caucasians. The extent of the rs1378942 effect was À1.42±0.34 and À0.62±0.13 in Koreans and Caucasians, respectively, showing a greater influence of genetic variations in CSK on Koreans. The results on DBP and hypertension were similar to those for SBP (data not shown). Abbreviations: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; KARE, Korean Association Resource; OR, odds ratio; SBP, systolic blood pressure; SNP, single-nucleotide polymorphism.
Age, sex, BMI and cohort were used as covariates; P-values are o0.10; sample size for 80% power at a¼0.05 is based on KARE parameters, including minor allele frequency, effect size and mean value of the markers.
DISCUSSION
We examined 27 SNPs that were associated with blood pressure in Global BPgen and CHARGE. Among them, 14 SNPs in 4 genes, ATP2B1, CSK, CYP17A1 and PLEKHA7, were recapitulated in the Korean population, implying that the functions of these genes in regulating blood pressure are conserved between ethnic groups. In support of this model, the effect sizes of three of the four SNPs that we examined were similar to those in Caucasians. The estimated sample size for 80% study power in Table 2 showed that our sample size was enough to exclude the false-negative result in most cases. However, we could not exclude the possibility that some negative results in this study might come from the low study power (1-b o80%) because the minor allele frequencies and effect sizes of the SNPs in Koreans were different from those in Caucasians. ATP2B1 belongs to the family of P-type primary ion transport ATPases. ATP2B1 regulates the homeostasis of cellular calcium ion levels, which is important in controlling vascular smooth muscle contraction and dilation. 13, 14 However, it has been difficult to speculate the exact role of ATP2B1 in physiology because of the large number of isoforms and the multiplicity of interacting molecules. 15 Related to its role in blood pressure, it is not clear yet whether ATP2B1 directly regulates the contraction and dilation of vascular smooth muscle by pumping out intracellular Ca ++ or it indirectly regulates the blood pressure by transmitting signals from vascular endothelial cells into the vascular smooth muscle cells.
CSK is a member of nonreceptor tyrosine kinases, which are widely expressed in human tissues. 16 To date, at least 14 members have been identified, of which the 60-kDa c-Src is the prototype. 16 Of the many Src kinases, c-Src is highly expressed in vascular smooth muscle cells. 17 It is rapidly activated by angiotensin II and regulates signaling events that are associated with vascular smooth muscle cell contraction, growth and migration. [18] [19] [20] The direct involvement of CSK in mediating blood pressure was not known until the results of recent blood pressure GWASs. We are interested in validating the underlying mechanism of CSK in blood pressure regulation through angiotensin II and vascular smooth muscle cell contraction.
CYP17A1 encodes a member of the cytochrome P450 superfamily of enzymes. 21 The cytochrome P450 proteins are monooxygenases that catalyze many reactions in drug metabolism and synthesis of cholesterol, steroids and other lipids. Because CYP17A1 has both 17a-hydroxylase and 17,20-lyase activity, a deficiency in CYP17A1 activity causes congenital disorders that are characterized by sexual infantilism and hypertension. 22, 23 A total of 66 cases of mutations in CYP17A1 have been reported (Human Gene Mutation Database: www.hgmd.cf.ac.uk), in more than 15 cases of which patients suffered from hypertension, strongly suggesting that CYP17A1 regulates blood pressure. One possible underlying mechanism proposes that overexpression of mineralocorticoids in patients who lack CYP17A1 causes hypokalemic hypertension. 24 Our study, in addition to the two GWASs on blood pressure, confirmed the involvement of CYP17A1 in blood pressure, and we sought to analyze the differences in levels of mineralocorticoids-such as deoxycorticosterone and corticosterone-renin and aldosterone in the blood of individuals who bear different CYP17A1 genotypes.
The function of PLEKHA7 was unknown until last year, when it was reported to be a component of the zonula adherens, a specialized cadherin-based cell-cell junction. 25 PLEKHA7 seems to promote the incorporation of cadherin clusters, including E-cadherin and p120-catenin, into the higher-order structure of the zonula adherens. Many functions have been proposed for the zonula adherens beyond basic cadherin adhesion, including cell signaling. However, it is difficult to determine how PLEKHA7 affects blood pressure. One method of examining PLEKHA7 function in blood pressure would be to identify patients who have mutations in PLEKHA7 and show familial hypertension. A pathophysiological study in these patients might provide definitive results. Another means might to develop a mouse that overexpresses or underexpresses PLEKHA7 and measure the phenotypic changes that occur. Because the prevalence, age of onset, severity and complications of hypertension vary between ethnic groups, we assume that the contributions of dissimilar gene sets differentially affect the development of hypertension in diverse populations. 3 However, the consistent results in this study, suggest that some genetic architecture that affects the development of essential hypertension is similar between Europeans and Asians. It should also be noted that our conclusion is limited by the other 24 SNPs that were associated in the previous GWASs but not tested in this study. Moreover, the allele frequencies of SNPs replicated in Koreans were quite different from those in Caucasians, drawing the possibility that the effect of susceptibility loci may be different between Caucasians and Koreans at the population level.
